Agilus Diagnostics Limited
Healthcare · Diagnostics
Awaiting a verified source quote. No third-party quote is on record for this company yet, so there is no indicative price to show — and we would rather leave it blank than print a number we cannot stand behind. Our team can confirm the current dealable level directly.
Indicative private-market reference — not an exchange quote. Not investment advice.
- Implied valuation
- Not available
- Revenue growth
- Not disclosed
- EBITDA margin
- Not disclosed
- Prospera Score
- Not yet scored
What the market says, and what we know.
Two separate things, deliberately shown side by side: a sourced private-market price reference, and the depth of research that actually stands behind this company today.
No third-party quote has been sourced for this company yet, so there is no market reference to show. Ask us to check the current level and we will come back with what the market is actually doing.
- Research Universe — availableCatalogued as a strategically relevant private-market company.
- Basic Research — availableBusiness and ownership facts verified against primary sources — 2 sourced records on file.
- Deep Research — not availableNot started. No financials, no implied valuation and no Prospera Score exist for this company.
- Prospera Recommendation — not availableNo Prospera view has been published. Presence in the universe is not a recommendation.
Indicative Private-Market Price History
Real, dated third-party observations only — plotted where they exist, never interpolated, extended or carried forward. This is a record of private-market sightings, not a live exchange chart.
Price history not available. No dated third-party quotes have been sourced for this company yet.
The business, in plain English.
Assembled only from records that exist for this company. Anything not disclosed says so.
- Founded
- 1995
- Headquarters
- Gurugram, Haryana
- Sector
- Healthcare · Diagnostics
- Promoters
- Not disclosed
What it does
Agilus Diagnostics, renamed in 2023 from SRL Diagnostics, is one of India's largest diagnostic-testing chains by number of laboratories and revenue, offering pathology and radiology testing through a nationwide network of labs and collection centres. Originally incorporated in 1995 as Super Religare Laboratories, it is majority owned by listed hospital operator Fortis Healthcare, with International Finance Corporation, NYLIM and Resurgence PE holding the remainder. The company filed a DRHP for an IPO in September 2023 but withdrew it in February 2024 amid weak offer-for-sale market conditions.
Source: Business Standard / WikipediaWhy it matters
Competes with listed diagnostics chains Dr. Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies.
Source: Not attributedOwnership structure
Majority owned by listed hospital operator Fortis Healthcare (about 58%), with International Finance Corporation, NYLIM and Resurgence PE Investments holding the remaining minority stakes
Private-market context
Unlisted; previously filed DRHP for an IPO which was later withdrawn
What to understand before investing
- Unlisted shares can be difficult to sell. There may be no continuous market and no guaranteed buyer at the price you see.
- Any price shown here is an indicative private-market reference, not an exchange quote and not an executable price.
- An expected IPO may be delayed, repriced or never happen at all.
- A good company can still be a poor investment at the wrong valuation.
Research is not yet complete for this company.
We would rather say that plainly than publish a page that looks finished.
No financials, no implied valuation and no peer comparison have been researched for this company yet.
No Prospera Private Market Score and no Prospera view exist. Being in our universe is not a recommendation, and we will not manufacture one to fill this space.
What you can rely on above is what has actually been verified: the company's identity and business facts, any sourced price observations on record, and any risks that have been documented. If you want us to prioritise deeper work here, ask — that is genuinely how the queue gets set.
What could go wrong.
Documented, per-company risks — grouped by the categories the research itself recorded. There is no risk score here, because we do not compute one.
Governance
1 recorded riskMajority shareholder Fortis Healthcare underwent a major promoter fraud scandal under its original Singh-family promoters roughly a decade ago; while Fortis is now controlled by Malaysia's IHH Healthcare under new management, the legacy history is a governance factor relevant to any future listing of its diagnostics subsidiary.
Source: Wikipedia / Fortis Healthcare corporate historyIPO
1 recorded riskThe company already withdrew a DRHP once, in February 2024, after filing in September 2023, and has not publicly re-filed as of 2026.
Source: SEBI filing reportingWhat's happened, and why it matters.
Dated, sourced events only — recorded as they were reported, in reverse order of significance to a private-market holder.
- Other12 Feb 2024
Withdraws IPO filing
Ended the company's first public-listing attempt, leaving majority shareholder Fortis Healthcare's exit route via IPO unresolved.
Source: SEBI filing reporting - DRHP Filed30 Sept 2023
Files DRHP for IPO via offer-for-sale
First attempt to take India's largest diagnostics chain by lab count public.
Source: Business Standard
Everything traceable.
Every figure on this page comes from one of the records below. Where a source published a link, it is here.
| Field | Source | As of |
|---|---|---|
| Business Description | Business Standard / Wikipedia | Not disclosed |
| Competitive Position | Not attributed | Not disclosed |
Interested in Agilus Diagnostics Limited?
Every option below opens a conversation with a person at Prospera. Nothing here places, reserves or executes an order.
We will come back with the current dealable level, the available lot size and what the process actually involves. Indicative prices shown on this page are private-market references, not executable quotes.